Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Pharmacy teams should rely on program requirements and prescriber documentation rather than determining eligibility at the pharmacy counter Key details Program timeframe: July 1, 2026, through December 31, 2027 Eligible population: Medicare Part D beneficiaries enrolled in an eligible prescription drug plan who meet CMS eligibility criteria, including the programs clinical requirements for weight management
Nakamura et al
Tirzepatide : Combines GLP-1 activity with another hormone, GIP (glucose-dependent insulinotropic polypeptide), enhancing its effects on appetite suppression and metabolic health
Stability under ICH Q1A/Q1B protocols, with batch-specific CoA and third-party tested documentation, and FDA, EMA, CDSCO, FSSAI-ready dossiers
Are GLP-1 Injections right for me
